GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » Capex-to-Operating-Income

Navco Pharmaceuticals (TSXV:NAV) Capex-to-Operating-Income : 0.00 (As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Navco Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2023 was C$0.00 Mil. Its Operating Income for the three months ended in Mar. 2023 was C$0.01 Mil.

Hence, Navco Pharmaceuticals's Capex-to-Operating-Income for the three months ended in Mar. 2023 was 0.00.


Navco Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Navco Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals Capex-to-Operating-Income Chart

Navco Pharmaceuticals Annual Data
Trend Jun18 Jun19 Jun20 Jun21
Capex-to-Operating-Income
- - - -

Navco Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Navco Pharmaceuticals's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navco Pharmaceuticals's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Navco Pharmaceuticals's Capex-to-Operating-Income falls into.



Navco Pharmaceuticals Capex-to-Operating-Income Calculation

Navco Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2021 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.08
=N/A

Navco Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 0.007
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Navco Pharmaceuticals  (TSXV:NAV) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Navco Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Navco Pharmaceuticals (TSXV:NAV) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7
Website
Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.